A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
William R. Schelman, Glenn Liu, George Wilding, Thomas Morris, De Phung, Robert DreicerVolume:
29
Language:
english
Pages:
8
DOI:
10.1007/s10637-009-9318-5
Date:
February, 2011
File:
PDF, 153 KB
english, 2011